Inhibikase Therapeutics Inc (IKT)
1.34
-0.02
(-1.11%)
USD |
NASDAQ |
May 02, 12:59
Inhibikase Therapeutics Enterprise Value: -4.354M for May 1, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| May 01, 2024 | -4.354M |
| April 30, 2024 | -3.599M |
| April 29, 2024 | -2.811M |
| April 26, 2024 | -2.023M |
| April 25, 2024 | -0.7751M |
| April 24, 2024 | -0.9721M |
| April 23, 2024 | -2.876M |
| April 22, 2024 | -4.256M |
| April 19, 2024 | 0.1442M |
| April 18, 2024 | 0.5382M |
| April 17, 2024 | 0.7352M |
| April 16, 2024 | 0.709M |
| April 15, 2024 | 1.162M |
| April 12, 2024 | 1.129M |
| April 11, 2024 | 1.523M |
| April 10, 2024 | 0.8666M |
| April 09, 2024 | 0.7352M |
| April 08, 2024 | 1.261M |
| April 05, 2024 | 1.195M |
| April 04, 2024 | 1.195M |
| April 03, 2024 | 0.8666M |
| April 02, 2024 | 0.8666M |
| April 01, 2024 | 0.9322M |
| March 28, 2024 | 0.7378M |
| March 27, 2024 | 1.645M |
| Date | Value |
|---|---|
| March 26, 2024 | 1.580M |
| March 25, 2024 | 1.062M |
| March 22, 2024 | 1.191M |
| March 21, 2024 | 1.062M |
| March 20, 2024 | 0.0254M |
| March 19, 2024 | -0.7518M |
| March 18, 2024 | -0.2337M |
| March 15, 2024 | 0.414M |
| March 14, 2024 | 0.5435M |
| March 13, 2024 | 1.191M |
| March 12, 2024 | 1.450M |
| March 11, 2024 | 2.487M |
| March 08, 2024 | 2.746M |
| March 07, 2024 | 2.422M |
| March 06, 2024 | 2.357M |
| March 05, 2024 | 2.163M |
| March 04, 2024 | 1.321M |
| March 01, 2024 | 0.6731M |
| February 29, 2024 | 0.1104M |
| February 28, 2024 | 0.4815M |
| February 27, 2024 | 0.729M |
| February 26, 2024 | 0.4815M |
| February 23, 2024 | -0.0134M |
| February 22, 2024 | 0.2341M |
| February 21, 2024 | 0.4815M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
-20.72M
Minimum
May 19 2022
100.20M
Maximum
Dec 23 2020
3.867M
Average
-4.498M
Median
Jan 20 2022
Enterprise Value Benchmarks
| Tenax Therapeutics Inc | -1.654M |
| BioRestorative Therapies Inc | -1.777M |
| Bio-Path Holdings Inc | 0.8283M |
| ADMA Biologics Inc | 1.601B |
| Hepion Pharmaceuticals Inc | -5.648M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -4.178M |
| Total Expenses (Quarterly) | 4.404M |
| EPS Diluted (Quarterly) | -0.64 |
| Earnings Yield | -266.4% |